
PureTech-Founded Celea Therapeutics Raises $180 Million to Accelerate Deupirfenidone Development for IPF
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation…











